Ascendis Pharma A/S (NASDAQ:ASND) Posts Earnings Results, Beats Estimates By $0.11 EPS

Ascendis Pharma A/S (NASDAQ:ASND) posted its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.11, Zacks reports. The company had revenue of $285.45 million during the quarter, compared to analyst estimates of $362.47 million.

Here are the key takeaways from Ascendis Pharma A/S’s conference call:

• FDA approval of a third TransCon product (YUVIWEL/TransCon CNP) for achondroplasia, with early U.S. uptake of more than 60 children prescribed within weeks and plans for selected international early access and an EU decision expected in Q4 2026.
• Q1 revenue totaled €247M (company cited ~€197M from its lead rare‑endocrine product and €44M from SKYTROFA), with operating profit €25M (10% margin), non‑IFRS net profit €18M, €573M cash on hand, a completed Nasdaq direct listing, redemption of convertible notes, and an agreed PRV sale for $187.5M.
• The Phase II COACH data for the TransCon CNP + TransCon hGH combination showed substantially greater Week‑52 efficacy versus monotherapy (height Z‑score, limb alignment, spinal canal and arm‑span improvements), which management says could reduce or eliminate the need for invasive limb/spine surgeries.
• Management decided to discontinue internal oncology development of TransCon IL‑2 β/γ despite encouraging Phase I/II signals, signaling a strategic pullback from oncology and potential loss of internal upside for that program.

Ascendis Pharma A/S Stock Performance

ASND stock traded up $3.24 on Tuesday, reaching $266.94. 357,874 shares of the company were exchanged, compared to its average volume of 727,888. Ascendis Pharma A/S has a 12 month low of $160.86 and a 12 month high of $271.89. The stock’s fifty day moving average price is $232.85 and its 200 day moving average price is $226.26. The firm has a market capitalization of $16.65 billion, a PE ratio of 30.79 and a beta of 0.39. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.00 and a quick ratio of 0.72.

Insider Buying and Selling at Ascendis Pharma A/S

In related news, Director Jean Jacques Bienaime purchased 400 shares of the firm’s stock in a transaction on Tuesday, May 26th. The shares were bought at an average cost of $237.80 per share, for a total transaction of $95,120.00. Following the transaction, the director directly owned 400 shares of the company’s stock, valued at approximately $95,120. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. Additional details regarding this sale are available in the official SEC disclosure. 40.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently added to or reduced their stakes in the company. Corient Private Wealth LLC raised its holdings in Ascendis Pharma A/S by 17.7% in the 4th quarter. Corient Private Wealth LLC now owns 3,393 shares of the biotechnology company’s stock valued at $724,000 after acquiring an additional 510 shares in the last quarter. Empowered Funds LLC lifted its position in shares of Ascendis Pharma A/S by 1.7% in the 4th quarter. Empowered Funds LLC now owns 36,697 shares of the biotechnology company’s stock worth $7,825,000 after acquiring an additional 620 shares during the period. XTX Topco Ltd bought a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth approximately $951,000. Virtus Investment Advisers LLC grew its holdings in shares of Ascendis Pharma A/S by 19.2% during the 4th quarter. Virtus Investment Advisers LLC now owns 3,100 shares of the biotechnology company’s stock worth $661,000 after purchasing an additional 500 shares in the last quarter. Finally, Spyglass Capital Management LLC grew its holdings in shares of Ascendis Pharma A/S by 6.9% during the 4th quarter. Spyglass Capital Management LLC now owns 415,549 shares of the biotechnology company’s stock worth $88,612,000 after purchasing an additional 26,902 shares in the last quarter.

Wall Street Analyst Weigh In

ASND has been the topic of a number of research analyst reports. Oppenheimer reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Tuesday, June 9th. Bank of America boosted their target price on shares of Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. Citigroup initiated coverage on shares of Ascendis Pharma A/S in a report on Monday, May 18th. They set a “buy” rating and a $355.00 price target for the company. Wall Street Zen downgraded Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Wedbush reiterated an “outperform” rating and issued a $273.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, April 9th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of “Buy” and an average price target of $295.39.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.